TG Therapeutics Inc (STU:NKB2)
€ 15.004 -0.278 (-1.82%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.36 PB Ratio: 15.79 GF Score: 73/100

Q1 2019 TG Therapeutics Inc Earnings Call Transcript

May 10, 2019 / 12:00PM GMT
Release Date Price: €6.88 (-4.31%)
Operator

Greetings and welcome to the TG Therapeutics First Quarter 2019 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Jenna Bosco. Please go ahead.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Thank you. Good morning and welcome to our conference call regarding TG Therapeutics' First Quarter 2019 Financial Results and Business Update. I am Jenna Bosco, TG's Senior Vice President of Corporate Communications and I welcome you to our conference call today.

Following our safe harbor statement, Sean Power, TG's Chief Financial Officer, will provide a brief overview of our financial results and then turn the call over to Michael Weiss, the company's Executive Chairman and Chief Executive Officer, who will provide an update on the ongoing development of our lead compounds, ublituximab and umbralisib, as well a high level overview of our early stage programs and overall company standing.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot